278 related articles for article (PubMed ID: 25522361)
1. Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes.
Paape D; Bell AS; Heal WP; Hutton JA; Leatherbarrow RJ; Tate EW; Smith DF
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3363. PubMed ID: 25522361
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani.
Corpas-Lopez V; Moniz S; Thomas M; Wall RJ; Torrie LS; Zander-Dinse D; Tinti M; Brand S; Stojanovski L; Manthri S; Hallyburton I; Zuccotto F; Wyatt PG; De Rycker M; Horn D; Ferguson MAJ; Clos J; Read KD; Fairlamb AH; Gilbert IH; Wyllie S
ACS Infect Dis; 2019 Jan; 5(1):111-122. PubMed ID: 30380837
[TBL] [Abstract][Full Text] [Related]
3. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
Jain SK; Sahu R; Walker LA; Tekwani BL
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.
Voak AA; Standing JF; Sepúlveda N; Harris A; Croft SL; Seifert K
J Antimicrob Chemother; 2018 May; 73(5):1314-1323. PubMed ID: 29506127
[TBL] [Abstract][Full Text] [Related]
5. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
6. A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.
Tegazzini D; Díaz R; Aguilar F; Peña I; Presa JL; Yardley V; Martin JJ; Coteron JM; Croft SL; Cantizani J
Antimicrob Agents Chemother; 2016 Jun; 60(6):3524-32. PubMed ID: 27021313
[TBL] [Abstract][Full Text] [Related]
7. In vitro 4-Aryloxy-7-chloroquinoline derivatives are effective in mono- and combined therapy against Leishmania donovani and induce mitocondrial membrane potential disruption.
Valdivieso E; Mejías F; Torrealba C; Benaim G; Kouznetsov VV; Sojo F; Rojas-Ruiz FA; Arvelo F; Dagger F
Acta Trop; 2018 Jul; 183():36-42. PubMed ID: 29604246
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs.
Bell AS; Mills JE; Williams GP; Brannigan JA; Wilkinson AJ; Parkinson T; Leatherbarrow RJ; Tate EW; Holder AA; Smith DF
PLoS Negl Trop Dis; 2012; 6(4):e1625. PubMed ID: 22545171
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani.
Zahid MSH; Johnson MM; Tokarski RJ; Satoskar AR; Fuchs JR; Bachelder EM; Ainslie KM
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():125-132. PubMed ID: 31493763
[TBL] [Abstract][Full Text] [Related]
10. Novel Thienopyrimidine Inhibitors of
Bell AS; Yu Z; Hutton JA; Wright MH; Brannigan JA; Paape D; Roberts SM; Sutherell CL; Ritzefeld M; Wilkinson AJ; Smith DF; Leatherbarrow RJ; Tate EW
J Med Chem; 2020 Jul; 63(14):7740-7765. PubMed ID: 32575985
[TBL] [Abstract][Full Text] [Related]
11. Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine.
Tegazzini D; Cantizani J; Peña I; Martín J; Coterón JM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005629. PubMed ID: 28542202
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.
Vermeersch M; da Luz RI; Toté K; Timmermans JP; Cos P; Maes L
Antimicrob Agents Chemother; 2009 Sep; 53(9):3855-9. PubMed ID: 19546361
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.
Lamotte S; Aulner N; Späth GF; Prina E
Sci Rep; 2019 Jan; 9(1):438. PubMed ID: 30679614
[TBL] [Abstract][Full Text] [Related]
14. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
15. Rapid fluorescent assay for screening drugs on Leishmania amastigotes.
Shimony O; Jaffe CL
J Microbiol Methods; 2008 Oct; 75(2):196-200. PubMed ID: 18573286
[TBL] [Abstract][Full Text] [Related]
16. Bio-guided isolation of anti-leishmanial natural products from Diospyros gracilescens L. (Ebenaceae).
Njanpa CAN; Wouamba SCN; Yamthe LRT; Dize D; Tchatat BMT; Tsouh PVF; Pouofo MN; Jouda JB; Ndjakou BL; Sewald N; Kouam SF; Boyom FF
BMC Complement Med Ther; 2021 Mar; 21(1):106. PubMed ID: 33789661
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against
Phan TN; Baek KH; Lee N; Byun SY; Shum D; No JH
Molecules; 2020 Apr; 25(8):. PubMed ID: 32340370
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
19. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.
Escobar P; Matu S; Marques C; Croft SL
Acta Trop; 2002 Feb; 81(2):151-7. PubMed ID: 11801222
[TBL] [Abstract][Full Text] [Related]
20.
Tadele M; Abay SM; Makonnen E; Hailu A
Drug Des Devel Ther; 2020; 14():1307-1317. PubMed ID: 32280200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
